Biomaterial Database

Prostatic adenocarcinoma with cutaneous metastases overlying oestrogen-induced gynaecomastia. 1998

J Marcoval, and A Moreno, and A Jucglà, and O Servitje, and J Peyrí

Department of Dermatology, Ciutat Sanitària i Universitària de Bellvitge, Barcelona, Spain.

Carcinoma of the prostate gland is the second most frequent malignancy in males, accounting for 17% of cancer in men; between a third and one-half of these patients will have distant metastases at onset, but rarely cutaneous. We now report a case of prostatic adenocarcinoma with such metastases involving the right nipple and periareolar skin, overlying an area of hormone-induced gynaecomastia.

UI	MeSH Term	Description	Entries
D008297	Male		Males
D011471	Prostatic Neoplasms	Tumors or cancer of the PROSTATE.	Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D004961	Estramustine	A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.	Estramustinphosphate,Emcyt,Estracyt,Estramustin Phosphate,Estramustine Phosphate Sodium,Leo-275,NSC-89199,Leo 275,Leo275,NSC 89199,NSC89199,Phosphate Sodium, Estramustine,Phosphate, Estramustin
D006177	Gynecomastia	Enlargement of the BREAST in the males, caused by an excess of ESTROGENS. Physiological gynecomastia is normally observed in NEWBORNS; ADOLESCENT; and AGING males.	Adolescent Gynecomastia,Infant Gynecomastia,Male Breast Enlargement,Newborn Gynecomastia,Breast Enlargement, Male,Enlargement, Male Breast,Gynecomastia, Adolescent,Gynecomastia, Infant,Gynecomastia, Newborn
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230	Adenocarcinoma	A malignant epithelial tumor with a glandular organization.	Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000368	Aged	A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available.	Elderly
D012878	Skin Neoplasms	Tumors or cancer of the SKIN.	Cancer of Skin,Skin Cancer,Cancer of the Skin,Neoplasms, Skin,Cancer, Skin,Cancers, Skin,Neoplasm, Skin,Skin Cancers,Skin Neoplasm
D017809	Fatal Outcome	Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.	Fatal Outcomes,Outcome, Fatal,Outcomes, Fatal
D018931	Antineoplastic Agents, Hormonal	Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)	Hormonal Antineoplastic Agents,Antineoplastic Drugs, Hormonal,Antineoplastic Hormonal Agents,Antineoplastic Hormonal Drugs,Antineoplastics, Hormonal,Hormonal Agents, Antineoplastic,Hormonal Antineoplastic Drugs,Hormonal Antineoplastics,Agents, Antineoplastic Hormonal,Drugs, Antineoplastic Hormonal,Hormonal Drugs, Antineoplastic

Related Publications

J Marcoval, and A Moreno, and A Jucglà, and O Servitje, and J Peyrí

Cutaneous metastases of prostatic adenocarcinoma.

January 2015, Journal of cytology,

J Marcoval, and A Moreno, and A Jucglà, and O Servitje, and J Peyrí

Cutaneous metastases of prostatic adenocarcinoma in two dogs.

September 2020, Veterinary clinical pathology,

J Marcoval, and A Moreno, and A Jucglà, and O Servitje, and J Peyrí

A case of prostatic adenocarcinoma with NKX3.1-positive cutaneous metastases.

December 2020, International journal of dermatology,

J Marcoval, and A Moreno, and A Jucglà, and O Servitje, and J Peyrí

Phyllodes tumor in a male patient with bilateral gynaecomastia induced by oestrogen therapy for prostatic carcinoma.

April 1991, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,

J Marcoval, and A Moreno, and A Jucglà, and O Servitje, and J Peyrí

Percutaneous oestrogen- induced gynaecomastia: a case report.

April 1982, British journal of plastic surgery,

J Marcoval, and A Moreno, and A Jucglà, and O Servitje, and J Peyrí

Prostatic adenocarcinoma with endometrioid features treated with oestrogen.

September 1989, British journal of urology,

J Marcoval, and A Moreno, and A Jucglà, and O Servitje, and J Peyrí

Prostatic carcinoma with cutaneous metastases.

April 1973, British journal of urology,

J Marcoval, and A Moreno, and A Jucglà, and O Servitje, and J Peyrí

Prostatic carcinoma with diffuse cutaneous metastases.

September 1978, Urology,